Efficacy of pralidoxime in the treatment of organophosphorus poisoning

Study of the efficacy of pralidoxime in the treatment of organophosphorus poisoning

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170609034406N5

Enrollment

Registered

2020-07-06

Start date

2020-06-30

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orghanophosphate poisonous patients. Toxic effect of organophosphate and carbamate insecticides

Interventions

Intervention 1: Intervention group: 43 patients selected by simple random, concomitant treatment with atropine (0.5 mg / ml, Daropakhsh Company) (initial dose of 1-6 mg, which will be repeated every 3

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 12 years poisoning with a specific type of orghanophosphate similar patients in terms of severity of toxicity Not receiving pralidoxime before arrive hospital

Exclusion criteria

Exclusion criteria: Non-orghanophosphorous toxicity Pregnancy

Design outcomes

Primary

Measure	Time frame
Serum level of acetylcholinesterase enzyme. Timepoint: Daily measurement of serum acetylcholinesterase until the patient's day off. Method of measurement: ELISA kit.;Investigating the need for oxygen therapy in two groups including control and intervention. Timepoint: Momentary monitoring of the patient to assess the need for oxygen therapy. Method of measurement: Using the pulse oximeter device.;Investigating the need for intubation and the duration of intubation in the two groups of control and intervention. Timepoint: Using checklist to record the time of initiation and duration of intubation in patients with indication for intubation using data extracted from the patients medical files. Method of measurement: Already designed checklist for recording the time.;Investigating the need for mechanical ventilation and the duration of mechanical ventilation in two groups of control and intervention. Timepoint: Using checklist to record the time of mechanical ventilation and duration of mechanical ventilation in patients with indication for mechanical ventilation using data extracted from the patients medical files. Method of measurement: According to criteria exist for mechanical ventilation, the time of initiation and the time spent on mechanical ventilation for each patients will be recorded using data extracted from patients medical files.	—

Measure

Time frame

Serum level of acetylcholinesterase enzyme. Timepoint: Daily measurement of serum acetylcholinesterase until the patient's day off. Method of measurement: ELISA kit.;Investigating the need for oxygen therapy in two groups including control and intervention. Timepoint: Momentary monitoring of the patient to assess the need for oxygen therapy. Method of measurement: Using the pulse oximeter device.;Investigating the need for intubation and the duration of intubation in the two groups of control and intervention. Timepoint: Using checklist to record the time of initiation and duration of intubation in patients with indication for intubation using data extracted from the patients medical files. Method of measurement: Already designed checklist for recording the time.;Investigating the need for mechanical ventilation and the duration of mechanical ventilation in two groups of control and intervention. Timepoint: Using checklist to record the time of mechanical ventilation and duration of mechanical ventilation in patients with indication for mechanical ventilation using data extracted from the patients medical files. Method of measurement: According to criteria exist for mechanical ventilation, the time of initiation and the time spent on mechanical ventilation for each patients will be recorded using data extracted from patients medical files.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Gharekhani

Tabriz University of Medical Sciences

gharekhania@tbzmed.ac.ir+98 41 3335 5921

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026